ClinicalTrials.gg
TerminatedNCT04688658Updated Dec 17, 2025Results posted

Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma

A Phase 1/2 interventional study of Nivolumab and Duvelisib in Unresectable Melanoma, sponsored by John Kirkwood. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by John Kirkwood · Phase 1/2, Interventional, and Treatment

How we know · 5 judgments

Why this study was terminated
Secura Bio, Inc. discontinued support of the trial.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 142 studies testing nivolumab in Melanoma — 32 open to participants now, 62 under way, 9 of them phase 3. Nivolumab · Melanoma.

Enrollment
112th of 142
13 · median 50
Started
2021
with 9 others
Phase 1/2
17 of 142
6 open now
Registered
90th of 142
by date

Among the 142 studies testing nivolumab in Melanoma, this one is the 112th largest by enrollment, is one of 10 that started in 2021, is one of 17 in phase 1/2, and was the 90th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

32 of the 142 studies testing nivolumab in Melanoma are open now, in 12 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies testing nivolumab in Melanoma, or all of them as a file.
02

Study summary

This trial is a Phase I/II study in which a combination of duvelisib and nivolumab will be used to treat a total of patients diagnosed with advanced unresectable melanoma who have progressed on anti-PD1 therapy. The Recommended Phase II Dose of oral duvelisib will be determined and administered with intravenous nivolumab 480mg for up to 1 year or until the patient's disease does not progress or the patient experiences unacceptable side effects to treatment.

Read the detailed description

This trial will study of PI3Kγδ inhibitor duvelisib in combination with nivolumab in patients with advanced unresectable melanoma who have progressed on anti-PD1 therapy. In the Phase I part of the study (18) patients will be administered nivolumab 480mg intravenously and duvelisib orally in doses from 15mg once a day to 25mg twice a day to determine the recommended dose for the Phase II part of the study. In the Phase II study patients will be administered nivolumab 480mg intravenously and duvelisib orally (dose not determined until the Phase 1 study is completed) up to 1 year as long as their disease doesn't progress or have unacceptable side effects to the study drugs. This trial will attempt to determine whether duvelisib acts as an immunomodulator, to shift the TME from an immunosuppressive to an immunostimulatory setting, to overcome acquired resistance in anti-PD1 treated patients. The phase I portion of the study is uniquely designed to find the ideal dose of duvelisib as an immunomodulator, which is suspected to be lower than the previously determined maximum tolerated dose (MTD) of duvelisib in lymphoma studies.

03

Conditions studied

  • Unresectable Melanoma

Browse trials for

Keywords

  • Anti-PD-1 monoclonal antibody (mAb)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • AJCC 8th edition criteria for unresectable stage IIIB, stage IIIC, stage IIID or stage IV melanoma who have received at least 3 months of prior treatment with an anti-PD1 or anti-PDL1 antibody and who have progressed on this treatment. Patients who have received a combination anti-PD1 and anti-CTLA4 therapy who exhibit progression at this interval are also permitted. There are no restrictions regarding time since last anti-PD1 treatment, or number of therapies after anti-PD1.
  • Age ≥ 18 years
  • performance status ≤ 2 or ≥ 60%
  • Patients must have normal organ and bone marrow function as defined below:

    • ≥9.0 g/dL
    • ≥1500 cells/µL
    • ≥100,000 cells/µL
    • Total ≤ 1.5 x institutional (ULN). Patients with Gilbert's syndrome must have normal direct bilirubin
    • /ALT ≤2.5x ULN in subjects with liver , must be within normal limits for those without liver metastasis
    • Creatinine \< 1.5 mg/dL
  • For patients with actionable BRAF mutations, treatment with BRAF and MEK inhibitors prior to initiation on trial is recommended, unless patients are intolerant of therapy or choose not to pursue BRAF targeted therapy.
  • Patients must have , defined as at least one tumor lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥10mm with CT scan, MRI or by calipers if documented on clinical exam. If patients have a single lesion, the lesion must be amenable to without interfering with radiographic assessment as determined by one of the co-PIs.
  • Duvelisib and nivolumab therapy may be harmful for a developing fetus. Women of child bearing potential (WCBP) must have a negative urine or serum β human chorionic gonadotropin (βhCG) pregnancy test within 7 days before starting treatment. WCBP and men must agree to use highly effective (pharmacologic birth control, barrier methods or abstinence) prior to study entry and for the duration of study participation through 5 months after the last dose of study medication. Should a woman become pregnant while she or her partner are participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use highly effective contraception prior to the study, for the duration of study participation and 12 weeks following the last dose.
  • WCBP defined as a sexually mature woman who as not undergone surgical sterilization or who has not been naturally for at least 12 consecutive months for women >55 years of age
  • Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria

  • Patients with known or suspected with are excluded, unless the following criteria are met:

    • Subjects have controlled brain metastasis, defined as without radiographic progression for at least 4 weeks following treatment with stereotactic radiation and/or surgical treatment at the time of randomization
    • Subjects must be off without symptoms of CNS disease for at least 2 weeks prior to treatment
    • Subjects with signs or symptoms of brain metastasis are not eligible unless brain metastasis is ruled out by computed tomography or magnetic resonance imaging
  • Patients with uveal or mucosal melanoma are excluded
  • Subjects with an active, known or suspected disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders such as vitiligo, alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
  • Subjects with history of chronic liver disease, veno-occlusive disease, active alcohol abuse or illicit drug use other than marijuana or its derivatives
  • Uncontrolled or significant cardiovascular disease including but not limited to the following:

    • Myocardial infarction (MI) or stroke/ (TIA) within the 6 months prior to consent
    • Uncontrolled angina within the 3 months prior to consent
    • Any history of arrhythmias (such as ventricular tachycardia, ventricular fibrillation, torsades de pointes, or poorly controlled atrial fibrillation)
    • History of other clinically significant cardiovascular disease (i.e., cardiomyopathy, congestive heart failure with [NYHA] functional classification III-IV, pericarditis, significant pericardial effusion, significant coronary stent occlusion, poorly controlled deep venous thrombosis, etc)
    • Cardiovascular disease-related requirement for daily supplemental oxygen
    • Subjects with history of myocarditis, regardless of etiology
    • Baseline (LVEF) \<45%. ECHO/MUGA not required at screening unless history of significant cardiac history.
    • prolongation > 500 msec
  • Uncontrolled or significant pulmonary disease including but not limited to the following:

    • Obstructive or restrictive lung disease requiring home oxygen
    • Hospitalization with (COPD) exacerbation within the last 6 months
    • History or concurrent condition of interstitial lung disease of any severity
    • Prior history of pneumonitis of grade II or higher, regardless of cause
    • Patients with diagnosis of obstructive sleep apnea (OSA) who are compliant with prescribed therapy (nocturnal O2, CPAP or BiPAP) are allowed on study
  • Uncontrolled or significant infectious disease including but not limited to the following:

    • Ongoing treatment for systemic bacterial, fungal or viral infection at screening
    • Subjects are not excluded for antimicrobial, antifungal or antiviral prophylaxis if other inclusion/exclusion criteria are met
    • Active cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infection (i.e., subjects with known history of detectable viral load)
    • Infection with , , (HIV), or human T-lymphotropic virus type 1
    • Subjects with a positive hepatitis B surface antigen [HBsAg] or hepatitis C antibody [HCV Ab] will be excluded, unless documented treatment and resolution of hepatitis C treatment Subjects with a positive hepatitis B core antibody (HBcAb) must have negative hepatitis B virus (HBV) deoxyribonucleic acid (DNA) assay to be eligible, must receive prophylaxis with entecavir (or equivalent) concomitant with duvelisib treatment, and must be periodically monitored for HBV reactivation by institutional guidelines. If unable to receive prophylaxis, then case will be discussed with investigators to determine eligibility.
    • History of tuberculosis treatment within 2 years prior to enrollment
  • Patients with history of encephalitis, meningitis, or uncontrolled seizures in the year prior to
  • Ongoing chronic treatment with (e.g. cyclosporine) or systemic steroids > 10mg of prednisone or equivalent once daily. Topical and inhaled steroids are allowed.
  • Subjects with other uncontrolled medical conditions or other illnesses, laboratory findings or other factors that would, in the investigator's judgment, increase the risk to the subject associated with his or her participation in the study.
  • Patients who are receiving other therapies will be excluded
  • Patients who had a history of life-threatening toxicity related to prior immune therapy (e.g. , anti-PD1 or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) except those that are well controlled an unlikely to be an issue with standard countermeasures (e.g. endocrine disorders managed by hormone replacement).
  • Subjects with a history of grade II or greater immune-mediated colitis. Patients whose toxicity was clearly attributable to anti-CTLA-4 treatment (tolerated anti-PD1 after receiving anti-CTLA4) may still be allowed on trial.
  • Subjects with a history of grade II or greater pneumonitis or transaminitis.
  • Prior treatments with PI3K inhibitors
  • Subject has a known additional that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone therapy with curative intent, or treated in situ cervical cancer for which there is appropriate ongoing surveillance
  • Subject had therapy with radiation, surgery or chemotherapy within 4 weeks prior to time of consent and/or has not recovered from adverse events to due to prior therapy. Subjects should be adequately recovered from all toxicities, complications, or acute illnesses prior to starting investigational therapy.
  • A maximum of three patients who have received talimogene laherparepvec (T-vec) as prior therapy will be allowed to enroll in the Phase II portion of the study. However, study-related must be performed at a disease site that was not injected with T-vec or adjacent to a T-vec injection site.
  • Subjects who are unable or unwilling to take prophylaxis for Pneumocystis jirovecii, human simplex virus (HSV) or herpes zoster (VZV) at time of screening
  • Subjects with known to duvelisib and/or its : Microcrystalline cellulose and magnesium stearate
  • Prisoners or subjects who are involuntarily incarcerated
  • Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness
  • Subjects who are unable or unwilling to comply with restrictions and prohibited activities and treatments
  • Subjects who are unable or unwilling to undergo venipuncture or tolerate venous access
  • Subjects with prior surgery and/or chronic gastrointestinal dysfunction that may affect drug absorption, such as gastric bypass, gastrectomy, malabsorption, inflammatory bowel disease, chronic diarrhea
  • Concurrent administration of medications or foods that are strong inhibitors of inducers of cytochrome p450 3A () within 2 weeks prior to study intervention. Duvelisib can increase exposure to CYP3A4 substrates; consider dose reduction of such substrates and monitor for signs of toxicities of co-administered sensitive CYP3A substrates.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Duvelisib plus Nivolumab

    Phase 1: Duvelisib will be taken orally in doses from 15mg once a day, 25mg once a day or 25mg twice a day, 12 hours a part, to determine the recommended dose for the Phase II study when combined with nivolumab. Nivolumab, 240mg, IV, every 2 weeks for the first four cycles; thereafter it may be switched to 480mg, IV, once every 4 weeks if deemed appropriate by the study doctor. Phase II: The Recommended Phase II dosage of duvelisib administered will not be determined until Phase I is completed. Nivolumab, 480mg, IV, every 4 weeks, for up to 1 year.

    Drug: Nivolumab · Drug: Duvelisib

Interventions

  • Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1. It is a type of immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.

    Also known as: Opdivo, AG013736

  • Duvelisib is a potent inhibitor of both γ and δ isoforms. Duvelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

    Also known as: Copiktra

06

What researchers measure

Primary outcomes

  1. DLTs by Phase I Dose of Duvelisib With Nivolumab

    Number of patients experiencing acute dose limiting toxicities (DLTs) and laboratory abnormalities considered possibly related to study treatment, occurring from the initial dose of duvelisib + nivolumab through day 28 of treatment (acute) or toxicities occurring from day 29 through 28 days after completion of treatment (late toxicities). DLTs are defined using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: Up to 56 days (per patient)

  2. Best Overall Response

    Best Response per RECIST v1.1: Completed Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10mm short axis); Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease (PD), taking as reference the smallest sum diameters while on study. Progressive Disease (PD): ≥20% (relative) increase in sum of diameters of target lesions referencing smallest sum on study (includes baseline sum if is smallest on study) and, the sum must also demonstrate an absolute increase of at least 5 mm; appearance of one or more new lesions.

    Time frame: Up to 29 months

  3. Best Overall Response Rate (ORR)

    Proportion of patients with a Best Response (CR+PR)/(CR+PR+SD+PD) per RECIST v1.1 of Completed Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10mm short axis); or Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to 29 months

  4. Change in CD 8+ TIL Frequency

    CyTek flow cytometry will be used to evaluate tumor-infiltrating cells in PBMCs and tumor tissue for the increased frequency (proliferation) and activation of CD8+ TILs. Proliferation of CD8+ TIL cells correlate with improved survival in patients with melanoma.

    Time frame: Baseline to Week 4

  5. Change in CD 8+ TIL Frequency

    CyTek flow cytometry will be used to evaluate tumor-infiltrating cells in PBMCs and tumor tissue for the increased frequency (proliferation) and activation of CD8+ TILs. Proliferation of CD8+ TIL cells correlate with improved survival in patients with melanoma.

    Time frame: Baseline to Week 12

  6. Change in CD 8+ TIL Frequency

    CyTek flow cytometry will be used to evaluate tumor-infiltrating cells in PBMCs and tumor tissue for the increased frequency (proliferation) and activation of CD8+ TILs. Proliferation of CD8+ TIL cells correlate with improved survival in patients with melanoma.

    Time frame: Week 4 to Week 12

Secondary outcomes

  1. Clinical Benefit

    Complete response \[CR\], partial response \[PR\] or stable disease \[SD\], per RECIST v1.1 criteria . Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes(whether target or non-target) must have reduction in short axis to \<10 mm. For non-target lesions: Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10mm short axis);PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD): ≥20% (relative) increase in sum of diameters of target lesions referencing smallest sum on study (includes baseline sum if is smallest on study) and, the sum must also demonstrate an absolute increase of at least 5 mm; appearance of one or more new lesions.

    Time frame: At Week 12

  2. Clinical Benefit

    Complete response \[CR\], partial response \[PR\], stable disease \[SD\], per RECIST v1.1 criteria . Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes(whether target or non-target) must have reduction in short axis to \<10 mm. For non-target lesions: Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10mm short axis);PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD): ≥20% (relative) increase in sum of diameters of target lesions referencing smallest sum on study (includes baseline sum if is smallest on study) and, the sum must also demonstrate an absolute increase of at least 5 mm; appearance of one or more new lesions.

    Time frame: At Week 24

  3. Clinical Benefit

    Complete response \[CR\], partial response \[PR\], stable disease \[SD\], per RECIST v1.1 criteria . Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes(whether target or non-target) must have reduction in short axis to \<10 mm. For non-target lesions: Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10mm short axis);PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD): ≥20% (relative) increase in sum of diameters of target lesions referencing smallest sum on study (includes baseline sum if is smallest on study) and, the sum must also demonstrate an absolute increase of at least 5 mm; appearance of one or more new lesions.

    Time frame: At Week 48

  4. Clinical Benefit Rate

    Proportion of patients (CR + PR + SD)/(CR + PR + SD +PD) Complete response \[CR\], partial response \[PR\], stable disease \[SD\], per RECIST v1.1 criteria. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes(whether target or non-target) must have reduction in short axis to \<10 mm. For non-target lesions: Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10mm short axis);PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD): ≥20% (relative) increase in sum of diameters of target lesions referencing smallest sum on study (includes baseline sum if is smallest on study) and, the sum must also demonstrate an absolute increase of at le

    Time frame: At Week 12

  5. Acute Adverse Events at Least Possibly Related to Treatment

    Number and percentage of Acute adverse events as graded by CTCAE v5.0 in patients at each dosing interval and in the expansion cohort. Toxicity events include those that are possibly, probably or definitely related to study treatment per Criteria for Adverse Events version 5 (CTCAE v5.0).

    Time frame: Up to 4 weeks

  6. Late Adverse Events at Least Possibly Related to Treatment

    Number and percentage of Late occurring adverse events as graded by CTCAE v5.0 in patients at each dosing interval and in the expansion cohort. Toxicity events include those that are possibly, probably or definitely related to study treatment per Criteria for Adverse Events version 5 (CTCAE v5.0).

    Time frame: Beginning at 4 weeks after start of treatment, up to 14 months

  7. Treatment Related Adverse Events

    Number of patients who experienced adverse events that are possibly, probably or definitely related to study treatment per Criteria for Adverse Events version 5 (CTCAE v5.0).

    Time frame: Up to 42.5 months

  8. Treatment Related Serious Adverse Events

    Number of patients who experienced serious adverse events that are possibly, probably or definitely related to study treatment per Criteria for Adverse Events version 5 (CTCAE v5.0).

    Time frame: Up to 42.5 months

  9. Treatment-related Grade 3 or Higher AE

    Number of Patients with Treatment-related Grade 3 or Higher AE per CTCAE v5.0

    Time frame: Up to 42.5 months

  10. Number of Patients With Clinical Response

    Number of patients with Complete Response (CR) or Partial Response (PR) until the first time at which progressive disease is objectively documented per RECIST v1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes(whether target or non-target) must have reduction in short axis to \<10 mm. For non-target lesions: Disappearance of all non-target lesions and normalization of tumormarker level. All lymph nodes must be non-pathological in size (\<10mm short axis);PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to 36 months

  11. Overall Survival (OS)

    The (median) length of time from the start of treatment that patients remain alive, until death from any cause. Patients who are alive will be censored at the time of the last follow-up.

    Time frame: Up to 25 months

  12. 6-month Overall Survival (OS)

    The percentage of patients alive at 6 months the start of treatment until death from any cause.

    Time frame: At 6 months

  13. 12-month Overall Survival (OS)

    The percentage of patients alive at 12 months the start of treatment until death from any cause.

    Time frame: At 12 months

  14. 18-month Overall Survival (OS)

    The percentage of patients alive at 18 months the start of treatment until death from any cause.

    Time frame: At 18 months

  15. Overall Survival (OS) - Total Population

    The (median) length of time from the start of treatment that patients remain alive, until death from any cause. Patients who are alive will be censored at the time of the last follow-up.

    Time frame: Up to 25 months

  16. 6-month Overall Survival (OS) - Total Population

    The percentage of patients alive at 6 months the start of treatment until death from any cause.

    Time frame: At 6 months

  17. 12-month Overall Survival (OS) - Total Population

    The percentage of patients alive at 12 months the start of treatment until death from any cause.

    Time frame: At 12 months

  18. 18-month Overall Survival (OS) -Total Population

    The percentage of patients alive at 18 months the start of treatment until death from any cause.

    Time frame: At 18 months

  19. Progression-free Survival (PFS)

    The (median) length of time from the initial date of treatment to the date of documented progression, or the date of death due to any cause (in the absence of progression, whichever occurs first), with progression defined by RECIST v1.1. PerRECIST v1.1, progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. For non-target lesions, PD: Unequivocal progression of existing non-target lesions. The appearance of one or more new lesions is also considered progression.

    Time frame: Up to 36 months

  20. 6-month Progression-free Survival (PFS)

    The percentage of patients whose disease does not progress from initial date of treatment to at 6 months, with progression defined by RECIST v1.1. PerRECIST v1.1, progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. For non-target lesions, PD: Unequivocal progression of existing non-target lesions. The appearance of one or more new lesions is also considered progression.

    Time frame: At 6 months

  21. 12-month Progression-free Survival (PFS)

    The percentage of patients whose disease does not progress from initial date of treatment to at 12 months, with progression defined by RECIST v1.1. PerRECIST v1.1, progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. For non-target lesions, PD: Unequivocal progression of existing non-target lesions. The appearance of one or more new lesions is also considered progression.

    Time frame: At 12 months

  22. 18-month Progression-free Survival (PFS)

    The percentage of patients whose disease does not progress from initial date of treatment to at 18 months, with progression defined by RECIST v1.1. PerRECIST v1.1, progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. For non-target lesions, PD: Unequivocal progression of existing non-target lesions. The appearance of one or more new lesions is also considered progression.

    Time frame: At 18 months

  23. Progression-free Survival (PFS) - Total Population

    The (median) length of time from the initial date of treatment to the date of documented progression, or the date of death due to any cause (in the absence of progression, whichever occurs first), with progression defined by RECIST v1.1. PerRECIST v1.1, progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. For non-target lesions, PD: Unequivocal progression of existing non-target lesions. The appearance of one or more new lesions is also considered progression.

    Time frame: Up to 36 months

  24. 6-month Progression-free Survival (PFS) - Total Population

    The percentage of patients whose disease does not progress from initial date of treatment to at 6 months, with progression defined by RECIST v1.1. Per RECIST v1.1, progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. For non-target lesions, PD: Unequivocal progression of existing non-target lesions. The appearance of one or more new lesions is also considered progression.

    Time frame: At 6 months

  25. 12-month Progression-free Survival (PFS) - Total Population

    The percentage of patients whose disease does not progress from initial date of treatment to at 12 months, with progression defined by RECIST v1.1. PerRECIST v1.1, progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. For non-target lesions, PD: Unequivocal progression of existing non-target lesions. The appearance of one or more new lesions is also considered progression.

    Time frame: At 12 months

  26. 18-month Progression-free Survival (PFS) - Total Population

    The percentage of patients whose disease does not progress from initial date of treatment to at 18 months, with progression defined by RECIST v1.1. PerRECIST v1.1, progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. For non-target lesions, PD: Unequivocal progression of existing non-target lesions. The appearance of one or more new lesions is also considered progression.

    Time frame: At 18 months

Other outcomes

  1. Immune Cell Function

    Evaluation of peripheral blood mononuclear cells (PBMCs) using CyTek flow cytometry.

    Time frame: Baseline (prior to treatment), at 12 weeks after start of treatment; Up to 2 years (cohort)

  2. Immune Cell Function

    Evaluation of tumor-infiltrating cells from using CyTek flow cytometry.

    Time frame: Baseline (prior to treatment), at 12 weeks after start of treatment; Up to 2 years (cohort)

  3. Tumor Microenvironment (TME)

    Changes in the immune cell population using Vectra imaging.

    Time frame: Baseline (prior to treatment), at 12 weeks after start of treatment; Up to 2 years (cohort)

  4. Mechanism of Anti-PD1 Resistance

    Changes in gene expression in the tumor using Nanostring gene profiling.

    Time frame: Baseline (prior to treatment), at 12 weeks after start of treatment; Up to 2 years (cohort)

07

Results

Posted Dec 17, 2025

Participant flow

Participant flow — Overall Study
MilestoneDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
Started76
Completed76
Not completed00

Outcome measures

PrimaryDLTs by Phase I Dose of Duvelisib With Nivolumab

Number of patients experiencing acute dose limiting toxicities (DLTs) and laboratory abnormalities considered possibly related to study treatment, occurring from the initial dose of duvelisib + nivolumab through day 28 of treatment (acute) or toxicities occurring from day 29 through 28 days after completion of treatment (late toxicities). DLTs are defined using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Time frame:
Up to 56 days (per patient)
Reported as:
Number · participants
DLTs by Phase I Dose of Duvelisib With Nivolumab
participantsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
DLTs by Phase I Dose of Duvelisib With Nivolumab00
PrimaryBest Overall Response

Best Response per RECIST v1.1: Completed Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10mm short axis); Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease (PD), taking as reference the smallest sum diameters while on study. Progressive Disease (PD): ≥20% (relative) increase in sum of diameters of target lesions referencing smallest sum on study (includes baseline sum if is smallest on study) and, the sum must also demonstrate an absolute increase of at least 5 mm; appearance of one or more new lesions.

Time frame:
Up to 29 months
Reported as:
Count of participants · Participants
Best Overall Response
ParticipantsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
Partial Response (PR)10
Stable Disease (SD)11
Progressive Disease (PD)33
PrimaryBest Overall Response Rate (ORR)

Proportion of patients with a Best Response (CR+PR)/(CR+PR+SD+PD) per RECIST v1.1 of Completed Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10mm short axis); or Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Up to 29 months
Reported as:
Number · proportion of patients
Best Overall Response Rate (ORR)
proportion of patientsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
Best Overall Response Rate (ORR)0.20 (0.0051 to 0.7164)0.0 (0 to 0.6024)
PrimaryChange in CD 8+ TIL Frequency

CyTek flow cytometry will be used to evaluate tumor-infiltrating cells in PBMCs and tumor tissue for the increased frequency (proliferation) and activation of CD8+ TILs. Proliferation of CD8+ TIL cells correlate with improved survival in patients with melanoma.

Time frame:
Baseline to Week 4
Reported as:
Mean · percentage of cells
Change in CD 8+ TIL Frequency
percentage of cellsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
Total CD8 T-cells (%CD45)-0.87 ± 2.912.66 ± 3.65
Total Cycling CD8 (%Ki67+)2.86 ± 1.9410.26 ± 23.11
NAV. %CD8-2.52 ± 6.07-1.44 ± 6.61
TCM. %CD80.84 ± 3.89-0.22 ± 5.13
TEM %CD82.92 ± 4.601.46 ± 4.98
TEMRA. %CD8-1.25 ± 1.94-0.88 ± 7.09
SecondaryClinical Benefit

Complete response \[CR\], partial response \[PR\] or stable disease \[SD\], per RECIST v1.1 criteria . Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes(whether target or non-target) must have reduction in short axis to \<10 mm. For non-target lesions: Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10mm short axis);PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD): ≥20% (relative) increase in sum of diameters of target lesions referencing smallest sum on study (includes baseline sum if is smallest on study) and, the sum must also demonstrate an absolute increase of at least 5 mm; appearance of one or more new lesions.

Time frame:
At Week 12
Reported as:
Count of participants · Participants
Clinical Benefit
ParticipantsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
Partial Response (Week 12)10
Stable Disease (Week 12)01
Progressive Disease (Week 12)43
SecondaryClinical Benefit

Complete response \[CR\], partial response \[PR\], stable disease \[SD\], per RECIST v1.1 criteria . Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes(whether target or non-target) must have reduction in short axis to \<10 mm. For non-target lesions: Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10mm short axis);PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD): ≥20% (relative) increase in sum of diameters of target lesions referencing smallest sum on study (includes baseline sum if is smallest on study) and, the sum must also demonstrate an absolute increase of at least 5 mm; appearance of one or more new lesions.

Time frame:
At Week 24
Reported as:
Count of participants · Participants
Clinical Benefit
ParticipantsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
Clinical Benefit10
SecondaryClinical Benefit

Complete response \[CR\], partial response \[PR\], stable disease \[SD\], per RECIST v1.1 criteria . Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes(whether target or non-target) must have reduction in short axis to \<10 mm. For non-target lesions: Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10mm short axis);PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD): ≥20% (relative) increase in sum of diameters of target lesions referencing smallest sum on study (includes baseline sum if is smallest on study) and, the sum must also demonstrate an absolute increase of at least 5 mm; appearance of one or more new lesions.

Time frame:
At Week 48
Reported as:
Count of participants · Participants
Clinical Benefit
ParticipantsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
Clinical Benefit10
SecondaryClinical Benefit Rate

Proportion of patients (CR + PR + SD)/(CR + PR + SD +PD) Complete response \[CR\], partial response \[PR\], stable disease \[SD\], per RECIST v1.1 criteria. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes(whether target or non-target) must have reduction in short axis to \<10 mm. For non-target lesions: Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10mm short axis);PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD): ≥20% (relative) increase in sum of diameters of target lesions referencing smallest sum on study (includes baseline sum if is smallest on study) and, the sum must also demonstrate an absolute increase of at le

Time frame:
At Week 12
Reported as:
Number · proportion of patients
Clinical Benefit Rate
proportion of patientsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
Clinical Benefit Rate0.20 (0.0051 to 0.7164)0.25 (0.0063 to 0.8059)
SecondaryAcute Adverse Events at Least Possibly Related to Treatment

Number and percentage of Acute adverse events as graded by CTCAE v5.0 in patients at each dosing interval and in the expansion cohort. Toxicity events include those that are possibly, probably or definitely related to study treatment per Criteria for Adverse Events version 5 (CTCAE v5.0).

Time frame:
Up to 4 weeks
Reported as:
Count of participants · Participants
Acute Adverse Events at Least Possibly Related to Treatment
ParticipantsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
Anemia10
Diarrhea10
Vomiting01
Chills01
Fever01
CD4 lymphocytes decreased01
Hyponatremia10
Myalgia10
SecondaryLate Adverse Events at Least Possibly Related to Treatment

Number and percentage of Late occurring adverse events as graded by CTCAE v5.0 in patients at each dosing interval and in the expansion cohort. Toxicity events include those that are possibly, probably or definitely related to study treatment per Criteria for Adverse Events version 5 (CTCAE v5.0).

Time frame:
Beginning at 4 weeks after start of treatment, up to 14 months
Reported as:
Count of participants · Participants
Late Adverse Events at Least Possibly Related to Treatment
ParticipantsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
Hyperthyroidism20
Diarrhea01
Vomiting01
Hypothyroidism01
Dry mouth01
CD4 lymphocytes decreased10
Fatigue20
Hepatic failure01
Alanine aminotransferase increased33
Alkaline phosphatase increased11
Aspartate aminotransferase increased33
Blood bilirubin increased01
Lymphocyte count decreased01
Neutrophil count decreased01
White blood cell decreased01
Anorexia10
Generalized muscle weakness01
Proteinuria10
Hypertension10
SecondaryTreatment Related Adverse Events

Number of patients who experienced adverse events that are possibly, probably or definitely related to study treatment per Criteria for Adverse Events version 5 (CTCAE v5.0).

Time frame:
Up to 42.5 months
Reported as:
Count of participants · Participants
Treatment Related Adverse Events
ParticipantsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
Treatment Related Adverse Events55
SecondaryTreatment Related Serious Adverse Events

Number of patients who experienced serious adverse events that are possibly, probably or definitely related to study treatment per Criteria for Adverse Events version 5 (CTCAE v5.0).

Time frame:
Up to 42.5 months
Reported as:
Count of participants · Participants
Treatment Related Serious Adverse Events
ParticipantsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
Treatment Related Serious Adverse Events31
SecondaryTreatment-related Grade 3 or Higher AE

Number of Patients with Treatment-related Grade 3 or Higher AE per CTCAE v5.0

Time frame:
Up to 42.5 months
Reported as:
Count of participants · Participants
Treatment-related Grade 3 or Higher AE
ParticipantsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
Treatment-related Grade 3 or Higher AE44
SecondaryNumber of Patients With Clinical Response

Number of patients with Complete Response (CR) or Partial Response (PR) until the first time at which progressive disease is objectively documented per RECIST v1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes(whether target or non-target) must have reduction in short axis to \<10 mm. For non-target lesions: Disappearance of all non-target lesions and normalization of tumormarker level. All lymph nodes must be non-pathological in size (\<10mm short axis);PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Up to 36 months
Reported as:
Number · participants
Number of Patients With Clinical Response
participantsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
Number of Patients With Clinical Response10
SecondaryOverall Survival (OS)

The (median) length of time from the start of treatment that patients remain alive, until death from any cause. Patients who are alive will be censored at the time of the last follow-up.

Time frame:
Up to 25 months
Reported as:
Median · months
Overall Survival (OS)
monthsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
Overall Survival (OS)13.5 (12.2 to NA)4.9 (3.9 to NA)
Secondary6-month Overall Survival (OS)

The percentage of patients alive at 6 months the start of treatment until death from any cause.

Time frame:
At 6 months
Reported as:
Number · percentage of patients
6-month Overall Survival (OS)
percentage of patientsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
6-month Overall Survival (OS)80.0 (51.6 to 100.0)40.0 (13.7 to 100.0)
Secondary12-month Overall Survival (OS)

The percentage of patients alive at 12 months the start of treatment until death from any cause.

Time frame:
At 12 months
Reported as:
Number · percentage of patients
12-month Overall Survival (OS)
percentage of patientsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
12-month Overall Survival (OS)80.0 (51.6 to 100.0)20.0 (3.5 to 100.0)
Secondary18-month Overall Survival (OS)

The percentage of patients alive at 18 months the start of treatment until death from any cause.

Time frame:
At 18 months
Reported as:
Number · percentage of patients
18-month Overall Survival (OS)
percentage of patientsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
18-month Overall Survival (OS)40.0 (13.7 to 100.0)NA (NA to NA)
SecondaryOverall Survival (OS) - Total Population

The (median) length of time from the start of treatment that patients remain alive, until death from any cause. Patients who are alive will be censored at the time of the last follow-up.

Time frame:
Up to 25 months
Reported as:
Median · months
Overall Survival (OS) - Total Population
monthsDuvelisib (15mg and 25mg) + Nivolumab (240mg)
Overall Survival (OS) - Total Population9.9 (3.9 to NA)
Secondary6-month Overall Survival (OS) - Total Population

The percentage of patients alive at 6 months the start of treatment until death from any cause.

Time frame:
At 6 months
Reported as:
Number · percentage of patients
6-month Overall Survival (OS) - Total Population
percentage of patientsDuvelisib (15mg and 25mg) + Nivolumab (240mg)
6-month Overall Survival (OS) - Total Population60.0 (36.2 to 99.5)
Secondary12-month Overall Survival (OS) - Total Population

The percentage of patients alive at 12 months the start of treatment until death from any cause.

Time frame:
At 12 months
Reported as:
Number · percentage of patients
12-month Overall Survival (OS) - Total Population
percentage of patientsDuvelisib (15mg and 25mg) + Nivolumab (240mg)
12-month Overall Survival (OS) - Total Population50.0 (26.9 to 92.9)
Secondary18-month Overall Survival (OS) -Total Population

The percentage of patients alive at 18 months the start of treatment until death from any cause.

Time frame:
At 18 months
Reported as:
Number · percentage of patients
18-month Overall Survival (OS) -Total Population
percentage of patientsDuvelisib (15mg and 25mg) + Nivolumab (240mg)
18-month Overall Survival (OS) -Total Population30.0 (11.6 to 77.3)
SecondaryProgression-free Survival (PFS)

The (median) length of time from the initial date of treatment to the date of documented progression, or the date of death due to any cause (in the absence of progression, whichever occurs first), with progression defined by RECIST v1.1. PerRECIST v1.1, progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. For non-target lesions, PD: Unequivocal progression of existing non-target lesions. The appearance of one or more new lesions is also considered progression.

Time frame:
Up to 36 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
Progression-free Survival (PFS)2.8 (2.8 to NA)3.0 (2.8 to NA)
Secondary6-month Progression-free Survival (PFS)

The percentage of patients whose disease does not progress from initial date of treatment to at 6 months, with progression defined by RECIST v1.1. PerRECIST v1.1, progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. For non-target lesions, PD: Unequivocal progression of existing non-target lesions. The appearance of one or more new lesions is also considered progression.

Time frame:
At 6 months
Reported as:
Number · percentage of participants
6-month Progression-free Survival (PFS)
percentage of participantsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
6-month Progression-free Survival (PFS)20 (3.5 to 100.00)0 (NA to NA)
Secondary12-month Progression-free Survival (PFS)

The percentage of patients whose disease does not progress from initial date of treatment to at 12 months, with progression defined by RECIST v1.1. PerRECIST v1.1, progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. For non-target lesions, PD: Unequivocal progression of existing non-target lesions. The appearance of one or more new lesions is also considered progression.

Time frame:
At 12 months
Reported as:
Number · percentage of participants
12-month Progression-free Survival (PFS)
percentage of participantsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
12-month Progression-free Survival (PFS)0 (NA to NA)0 (NA to NA)
Secondary18-month Progression-free Survival (PFS)

The percentage of patients whose disease does not progress from initial date of treatment to at 18 months, with progression defined by RECIST v1.1. PerRECIST v1.1, progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. For non-target lesions, PD: Unequivocal progression of existing non-target lesions. The appearance of one or more new lesions is also considered progression.

Time frame:
At 18 months
Reported as:
Number · percentage of participants
18-month Progression-free Survival (PFS)
percentage of participantsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
18-month Progression-free Survival (PFS)0 (NA to NA)0 (NA to NA)
SecondaryProgression-free Survival (PFS) - Total Population

The (median) length of time from the initial date of treatment to the date of documented progression, or the date of death due to any cause (in the absence of progression, whichever occurs first), with progression defined by RECIST v1.1. PerRECIST v1.1, progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. For non-target lesions, PD: Unequivocal progression of existing non-target lesions. The appearance of one or more new lesions is also considered progression.

Time frame:
Up to 36 months
Reported as:
Median · months
Progression-free Survival (PFS) - Total Population
monthsDuvelisib (15mg and 25mg) + Nivolumab (240mg)
Progression-free Survival (PFS) - Total Population2.8 (2.6 to NA)
Secondary6-month Progression-free Survival (PFS) - Total Population

The percentage of patients whose disease does not progress from initial date of treatment to at 6 months, with progression defined by RECIST v1.1. Per RECIST v1.1, progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. For non-target lesions, PD: Unequivocal progression of existing non-target lesions. The appearance of one or more new lesions is also considered progression.

Time frame:
At 6 months
Reported as:
Number · percentage of patients
6-month Progression-free Survival (PFS) - Total Population
percentage of patientsDuvelisib (15mg and 25mg) + Nivolumab (240mg)
6-month Progression-free Survival (PFS) - Total Population10.0 (1.6 to 64.2)
Secondary12-month Progression-free Survival (PFS) - Total Population

The percentage of patients whose disease does not progress from initial date of treatment to at 12 months, with progression defined by RECIST v1.1. PerRECIST v1.1, progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. For non-target lesions, PD: Unequivocal progression of existing non-target lesions. The appearance of one or more new lesions is also considered progression.

Time frame:
At 12 months
Reported as:
Number · percentage of patients
12-month Progression-free Survival (PFS) - Total Population
percentage of patientsDuvelisib (15mg and 25mg) + Nivolumab (240mg)
12-month Progression-free Survival (PFS) - Total Population0 (NA to NA)
Secondary18-month Progression-free Survival (PFS) - Total Population

The percentage of patients whose disease does not progress from initial date of treatment to at 18 months, with progression defined by RECIST v1.1. PerRECIST v1.1, progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. For non-target lesions, PD: Unequivocal progression of existing non-target lesions. The appearance of one or more new lesions is also considered progression.

Time frame:
At 18 months
Reported as:
Number · percentage of participants
18-month Progression-free Survival (PFS) - Total Population
percentage of participantsDuvelisib (15mg and 25mg) + Nivolumab (240mg)
18-month Progression-free Survival (PFS) - Total Population0 (NA to NA)
Other pre-specifiedImmune Cell Function

Evaluation of peripheral blood mononuclear cells (PBMCs) using CyTek flow cytometry.

Time frame:
Baseline (prior to treatment), at 12 weeks after start of treatment; Up to 2 years (cohort)

Results for this outcome have not been posted.

Other pre-specifiedImmune Cell Function

Evaluation of tumor-infiltrating cells from using CyTek flow cytometry.

Time frame:
Baseline (prior to treatment), at 12 weeks after start of treatment; Up to 2 years (cohort)

Results for this outcome have not been posted.

Other pre-specifiedTumor Microenvironment (TME)

Changes in the immune cell population using Vectra imaging.

Time frame:
Baseline (prior to treatment), at 12 weeks after start of treatment; Up to 2 years (cohort)

Results for this outcome have not been posted.

Other pre-specifiedMechanism of Anti-PD1 Resistance

Changes in gene expression in the tumor using Nanostring gene profiling.

Time frame:
Baseline (prior to treatment), at 12 weeks after start of treatment; Up to 2 years (cohort)

Results for this outcome have not been posted.

PrimaryChange in CD 8+ TIL Frequency

CyTek flow cytometry will be used to evaluate tumor-infiltrating cells in PBMCs and tumor tissue for the increased frequency (proliferation) and activation of CD8+ TILs. Proliferation of CD8+ TIL cells correlate with improved survival in patients with melanoma.

Time frame:
Baseline to Week 12
Reported as:
Mean · percentage of cells
Change in CD 8+ TIL Frequency
percentage of cellsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
Total CD8 T-cells (%CD45)4.05 ± 5.03-1.63 ± 3.58
Total Cycling CD8 (%Ki67+)15.86 ± 24.960.45 ± 3.70
NAV. %CD8-3.79 ± 4.80-1.68 ± 2.37
TCM. %CD8-0.15 ± 3.23-8.91 ± 3.41
TEM %CD87.97 ± 6.606.60 ± 6.65
TEMRA. %CD8-4.06 ± 8.104.00 ± 0.85
PrimaryChange in CD 8+ TIL Frequency

CyTek flow cytometry will be used to evaluate tumor-infiltrating cells in PBMCs and tumor tissue for the increased frequency (proliferation) and activation of CD8+ TILs. Proliferation of CD8+ TIL cells correlate with improved survival in patients with melanoma.

Time frame:
Week 4 to Week 12
Reported as:
Mean · percentage of cells
Change in CD 8+ TIL Frequency
percentage of cellsDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
Total CD8 T-cells (%CD45)4.11 ± 4.59-2.69 ± 0.69
Total Cycling CD8 (%Ki67+)12.52 ± 26.542.92 ± 8.39
NAV. %CD81.44 ± 2.19-1.70 ± 5.51
TCM. %CD8-1.88 ± 3.02-13.26 ± 6.73
TEM %CD84.03 ± 5.856.75 ± 6.86
TEMRA. %CD8-3.62 ± 6.628.20 ± 5.37

Adverse events

Collected over Adverse events data collected for up to 42.5 months for the study population.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Duvelisib (15mg) + Nivolumab (240mg)7/7 (100%)6/7 (85.7%)7/7 (100%)
Duvelisib (25mg) + Nivolumab (240mg)5/6 (83.3%)4/6 (66.7%)6/6 (100%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
ConfusionPSYCHIATRIC DISORDERS0/72/6
Death NOSGENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS2/70/6
Alanine aminotransferase increasedINVESTIGATIONS2/71/6
Aspartate aminotransferase increasedINVESTIGATIONS2/71/6
Lung infectionINFECTIONS AND INFESTATIONS0/71/6
SepsisINFECTIONS AND INFESTATIONS0/71/6
Neoplasms benign, malignant and unspecified (incl cysts and polyps) -Other, specifyBrain |NeoplasmNEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)0/71/6
Edema cerebralNERVOUS SYSTEM DISORDERS0/71/6
EncephalopathyNERVOUS SYSTEM DISORDERS0/71/6
LethargyNERVOUS SYSTEM DISORDERS0/71/6
Most frequent other events
Showing 10 of 101
Most frequent other events
EventDuvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)
HyponatremiaMETABOLISM AND NUTRITION DISORDERS6/76/6
AnemiaBLOOD AND LYMPHATIC SYSTEM DISORDERS4/75/6
HyperglycemiaMETABOLISM AND NUTRITION DISORDERS2/75/6
Lymphocyte count decreasedINVESTIGATIONS5/72/6
AnorexiaMETABOLISM AND NUTRITION DISORDERS3/74/6
HypoalbuminemiaMETABOLISM AND NUTRITION DISORDERS3/74/6
ConstipationGASTROINTESTINAL DISORDERS4/71/6
FatigueGENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS4/73/6
Blood lactate dehydrogenase increasedINVESTIGATIONS4/73/6
NauseaGASTROINTESTINAL DISORDERS2/73/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Duvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)Total
Median66.00 (51.00 to 79.00)65.50 (49.00 to 77.00)66.00 (49.00 to 79.00)
Sex: Female, Male
Sex: Female, Male(Participants)Duvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)Total
Female538
Male235
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Duvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)Total
Hispanic or Latino000
Not Hispanic or Latino5611
Unknown or Not Reported202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Duvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White6612
More than one race000
Unknown or Not Reported101
BRAF Status
BRAF Status(Participants)Duvelisib (15mg) + Nivolumab (240mg)Duvelisib (25mg) + Nivolumab (240mg)Total
Mutant202
Wild Type (WT)5611
08

Study locations

1 site
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Feb 2024, 28 months.

Results were first posted in Dec 2025, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2020
First posted
Dec 30, 2020
StartActual
Oct 6, 2021
Primary completionActual
Feb 22, 2024
CompletionActual
Feb 1, 2025
Results first posted
Dec 17, 2025
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04688658
Lead sponsor
John Kirkwood
Collaborators
Secura Bio, Inc., Bristol-Myers Squibb
Responsible party
John Kirkwood (Professor of Medicine, University of Pittsburgh) — Sponsor-investigator
First posted
Dec 30, 2020
Start date
Oct 6, 2021
Primary completion
Feb 22, 2024
Completion
Feb 1, 2025
Results posted
Dec 17, 2025
Last update
Dec 17, 2025

Study contacts

John Kirkwood, MD
principal investigator · UPMC Hillman Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Duvelisib

Start the discussion